

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/008,062-Conf. #5735		
		Filing Date	October 19, 2001		
		First Named Inventor	David A. Rizzieri		
		Art Unit	1642 / 1643		
		Examiner Name	A. M. Harris, Ph.D.		
Sheet	1	of	1	Attorney Docket Number	20605/1203866-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
am	CA	Zalutsky et al., <i>Pharmacokinetics and tumor localization of ¹²⁵I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies</i> , <i>Cancer Res.</i> , vol. 49, pp. 2807-2813 (May 15, 1989)	
↓	CB	Zalutsky et al., <i>Monoclonal antibody and F(ab)₂ fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration</i> , <i>Cancer Res.</i> , vol. 50, pp. 4105-4110 (July 1, 1990)	
↓	CC	Rizzieri et al., <i>Phase I Trial study of ¹²⁵I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma</i> , <i>Clinical Observations, Interventions, And Therapeutic Trials</i> , vol. 104, no. 3, pp. 642-648 (August 1, 2004)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Am Harris</i>	Date Considered	16 November 2006
-----------------------	------------------	--------------------	------------------